Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(KSP-1007 + meropenem) by Sumitomo Pharma for Hospital Acquired Pneumonia (HAP): Likelihood of Approval
(KSP-1007 + meropenem) is under clinical development by Sumitomo Pharma and currently in Phase I for Hospital Acquired Pneumonia (HAP)....
(KSP-1007 + meropenem) by Sumitomo Pharma for Ventilator Associated Pneumonia (VAP): Likelihood of Approval
(KSP-1007 + meropenem) is under clinical development by Sumitomo Pharma and currently in Phase I for Ventilator Associated Pneumonia (VAP)....
(KSP-1007 + meropenem) by Sumitomo Pharma for Complicated Intra-Abdominal Infections: Likelihood of Approval
(KSP-1007 + meropenem) is under clinical development by Sumitomo Pharma and currently in Phase I for Complicated Intra-Abdominal Infections. According...